- Published
- September 14, 2026
- Journal
- Clinical & Experimental Dermatology and Therapies
- Authors
- The present randomized, Double-Blind, placebo-controlled clinical study evaluated the efficacy and safety of SPH-24, a proprietary botanical formulation containing standardized extracts of pomegranate (, ) peel and holy basil (, on objective measures of skin aging and skin health in healthy women with mild-to-moderate facial wrinkles. Eighty women aged 30-55 years were randomized in a 1:1 ratio to receive SPH-24 (300 mg/day) or placebo once daily for 12 weeks. Forehead wrinkle number, wrinkle area, and wrinkle area percentage were assessed using New Visage-LS® imaging. Secondary assessments included skin firmness and elasticity, skin hydration, transepidermal water loss (TEWL), melanin index, erythema, and skin tone parameters (L*, and Individual Typology Angle [ITA]) using validated instrumental methods. Safety was assessed through adverse event monitoring, laboratory investigations, vital signs, and physical examinations. SPH-24 significantly reduced forehead wrinkle number, wrinkle area, and wrinkle area percentage compared with placebo after 12 weeks, with reduction in wrinkle number evident from Week 4. Significant improvements were also observed in skin hydration, elasticity, TEWL, melanin index, erythema, and the a* colorimetric parameter. No significant treatment differences were observed for skin firmness (R0), or ITA values. SPH-24 was well tolerated, with no treatment-related adverse events, serious adverse events, or clinically significant laboratory or vital sign abnormalities reported. Daily supplementation with SPH-24 for 12 weeks significantly improved multiple objective measures of skin aging and skin health, particularly wrinkle burden, hydration, elasticity, epidermal barrier function, pigmentation, and erythema. These findings support the potential of SPH-24 as a botanical nutricosmetic for promoting healthy skin aging.
- DOI
- 10.29011/2575-8268.100249
- Evidence class
- human-study
- Record status
- published
- Match confidence
- 100%
- Citations
- 0
- Source feed
- OpenAlex
Automated source synopsisHuman study published by Clinical & Experimental Dermatology and Therapies, indexed because it matched monitored longevity research terms. Inclusion in this index does not establish that an intervention is effective or safe.
Evidence snapshotWhat the source actually supports
- Evidence stage
- Human study
- Study design
- article
- Evidence population
- Human evidence
- Participants
- Not reported
- Population
- Not reported
- Duration
- Not reported
- Intervention
- Comparator
- Not reported
- Outcomes measured
- Reported result
- No reusable finding-level result is available in this record.
Main limitationBibliographic metadata identifies the record but does not provide enough reusable detail to summarize its population, comparison, findings, or effect size.
Safety and approvalThis index record does not establish safety, effectiveness, dose, or suitability for any person. A publication record is not a regulatory approval or treatment recommendation.
Source supportBibliographic citation metadata and controlled indexing terms only. Read the linked source for methods and results.
Evidence stage · human-studyThis describes the study type, not whether an intervention is safe or effective.
Lab or animalHuman studyRandomized trialEvidence synthesis
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Skin ageing · 100%Title contains controlled term: skin aging. Source terminology contains: skin aging. Title supplies longevity context: aging.
Automated source check 70% · update recency 100%. These figures help sort records; they are not medical ratings.
BibTeX · RIS
